A. Teeple

发表

Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States

J. Curtis, S. Ginsburg, D. Walls, 2019, Current medical research and opinion.

Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real‐world data

T. Fitzgerald, E. Muser, J. Hetherington, 2019, Clinical and experimental dermatology.

The economic burden of psoriasis with high comorbidity among privately insured patients in the United States

M. Ladouceur, E. Muser, P. Lefebvre, 2019, Journal of medical economics.

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

T. Fitzgerald, Mobolaji O Olurinde, A. Near, 2022, Dermatology and Therapy.

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry

T. Fitzgerald, J. Walsh, J. Merola, 2021, Dermatology and Therapy.

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study

A. Armstrong, E. Muser, M. Song, 2020, The Journal of dermatological treatment.

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population

S. Feldman, T. Fitzgerald, Bingcao Wu, 2021, The Journal of dermatological treatment.

Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA

T. Fitzgerald, P. Lefebvre, D. Pilon, 2022, Dermatology and Therapy.

Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis

E. Muser, Bingcao Wu, Q. Cai, 2019, Journal of medical economics.

A multinational assessment of work‐related productivity loss and indirect costs from a survey of patients with psoriasis†

S. McElligott, S. Fakharzadeh, S. Fakharzadeh, 2019, The British journal of dermatology.

Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population

S. Feldman, T. Fitzgerald, Bingcao Wu, 2021, Dermatology.

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States

J. Curtis, S. Ginsburg, D. Walls, 2019, Current medical research and opinion.

Predicting Poor Outcomes Among Individuals Seeking Care for Major Depressive Disorder

J. Liberman, B. Ahmedani, J. Pesa, 2022, Psychiatric research and clinical practice.

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis

T. Fitzgerald, A. Teeple, 2020, The Journal of dermatological treatment.

Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis

E. Muser, A. Teeple, 2019, Journal of medical economics.

Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers

M. Ingham, A. Teeple, M. Kariburyo, 2017, Advances in Therapy.

The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, A. Armstrong, R. McLean, 2023, Advances in therapy.

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States

K. Joshi, D. Pilon, M. Zhdanava, 2023, Journal of medical economics.

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

P. Lefebvre, K. Joshi, D. Pilon, 2023, Current medical research and opinion.